Nature Communications (Mar 2021)
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
- Timothy Kottke,
- Jason Tonne,
- Laura Evgin,
- Christopher B. Driscoll,
- Jacob van Vloten,
- Victoria A. Jennings,
- Amanda L. Huff,
- Brady Zell,
- Jill M. Thompson,
- Phonphimon Wongthida,
- Jose Pulido,
- Matthew R. Schuelke,
- Adel Samson,
- Peter Selby,
- Elizabeth Ilett,
- Mark McNiven,
- Lewis R. Roberts,
- Mitesh J. Borad,
- Hardev Pandha,
- Kevin Harrington,
- Alan Melcher,
- Richard G. Vile
Affiliations
- Timothy Kottke
- Department of Molecular Medicine, Mayo Clinic
- Jason Tonne
- Department of Molecular Medicine, Mayo Clinic
- Laura Evgin
- Department of Molecular Medicine, Mayo Clinic
- Christopher B. Driscoll
- Department of Molecular Medicine, Mayo Clinic
- Jacob van Vloten
- Department of Molecular Medicine, Mayo Clinic
- Victoria A. Jennings
- Chester Beatty Laboratories, Division of Radiotherapy and Imaging, The Institute of Cancer Research
- Amanda L. Huff
- Department of Molecular Medicine, Mayo Clinic
- Brady Zell
- Department of Molecular Medicine, Mayo Clinic
- Jill M. Thompson
- Department of Molecular Medicine, Mayo Clinic
- Phonphimon Wongthida
- Department of Molecular Medicine, Mayo Clinic
- Jose Pulido
- Department of Molecular Medicine, Mayo Clinic
- Matthew R. Schuelke
- Department of Molecular Medicine, Mayo Clinic
- Adel Samson
- Leeds Institute of Medical Research, University of Leeds
- Peter Selby
- Leeds Institute of Medical Research, University of Leeds
- Elizabeth Ilett
- Leeds Institute of Medical Research, University of Leeds
- Mark McNiven
- Division of Gastroenterology and Hepatology, Mayo Clinic
- Lewis R. Roberts
- Division of Gastroenterology and Hepatology, Mayo Clinic
- Mitesh J. Borad
- Division of Hematology/Oncology, Mayo Clinic
- Hardev Pandha
- Faculty of Health and Medical Sciences, University of Surrey
- Kevin Harrington
- Chester Beatty Laboratories, Division of Radiotherapy and Imaging, The Institute of Cancer Research
- Alan Melcher
- Chester Beatty Laboratories, Division of Radiotherapy and Imaging, The Institute of Cancer Research
- Richard G. Vile
- Department of Molecular Medicine, Mayo Clinic
- DOI
- https://doi.org/10.1038/s41467-021-22115-1
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
Oncolytic viruses, such as vesicular stomatitis virus (VSV), are a promising class of cancer therapeutics. Here the authors report that a mutation in the CSDE1 gene renders cancer cells resistant to VSV replication and oncolysis, but a mutation-derived escape-associated neoantigen could be exploited for immunotherapy against treatment-resistant tumors.
